<DOC>
	<DOCNO>NCT02861105</DOCNO>
	<brief_summary>The purpose study assess efficacy LMWH treatment woman unexplained infertility negative immunological marker undergo ICSI .</brief_summary>
	<brief_title>The Effect LMWH ICSI Patients With Unexplained Infertility Negative Immunological Markers</brief_title>
	<detailed_description>Inclusion criterion : 1. patient undergo 1st trial ICSI 2. unexplained infertility 3. negative immunological marker include ACL ab , LAC , ANA , ATA , AnitdsDNA Exclusion criterion : 1. previous IVF/ICSI 2 . Any cause infertility 3 . Suspected and/or unexpected poor response ovulation induction 4. positive immunological marker 5 . Age &gt; 40 year . All participant undergo IVF/ICSI cycle use Long luteal phase protocol . dose gonadotropin calculate accord patient age BMI . All patient 2-3 embryo transfer D5 accord age . primary outcome LBR . secondary outcome include biochemical pregnancy rate clinical pregnancy rate .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>age le 38 year least 12 month infertility woman unexplained infertility age equal 38 year serum AMH level less equal 1 ng/ml patient anticoagulant therapy immunecompromised patient patient contraindication low molecular weight heparin positive immunological marker patient unexplained infertility male factor infertility refusal participation patient unexpected poor response induction ovulation</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>38 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>